Back to Directory
Last Updated: 09/06/2026
Kesmalea Therapeutics
London
Founded 2020
Small molecule protein degraders targeting oncology and CNS disease
Kesmalea Therapeutics is a biotechnology company developing oral small molecule therapeutics that modulate protein homeostasis through targeted protein degradation and stabilisation.
The company's platform is designed to convert the potency of protein degrader approaches into orally bioavailable, CNS-penetrant small molecules, addressing limitations of existing degrader technologies.
Current programmes target disease-relevant proteins in oncology and central nervous system diseases where existing treatments are inadequate.